γ-H2AX expression detected by immunohistochemistry correlates with prognosis in early operable non-small cell lung cancer

OncoTargets and Therapy

Volumn 5, Issue , 2012, Pages 309-314

  Matthaios, Dimitrios ^a   Foukas, Periklis G ^b   Kefala, Maria ^b   Hountis, Panagiotis ^c   Trypsianis, Grigorios ^a   Panayiotides, Ioannis G ^b   Chatzaki, Ekaterini ^a   Pantelidaki, Ekaterini ^d   Bouros, Demosthenes ^a   Karakitsos, Petros ^b   Kakolyris, Stylianos ^a  

^a DEMOCRITUS UNIVERSITY OF THRACE   (Greece)

^b NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^c ATHENS NAVAL HOSPITAL   (Greece)

^d EVANGELISMOS HOSPITAL   (Greece)

Author keywords

DNA damage response; H2AX; Non small cell lung cancer; P53; Prognosis

Indexed keywords

CASPASE 3; GAMMA H2AX; HISTONE H2AX; KI 67 ANTIGEN; PROTEIN P53; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL FEATURE; COHORT ANALYSIS; CONTROLLED STUDY; DNA DAMAGE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LARGE CELL CARCINOMA; LOBECTOMY; LUNG ADENOCARCINOMA; LUNG NON SMALL CELL CANCER; LUNG RESECTION; LUNG SQUAMOUS CELL CARCINOMA; LYMPH NODE DISSECTION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SURVIVAL RATE; SURVIVAL TIME; UNDIFFERENTIATED CARCINOMA;

EID: 84873916028     PISSN: 11786930     EISSN: None     Source Type: Journal    
DOI: 10.2147/OTT.S36995     Document Type: Article

References (30)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
3. Hoang T, Xu R, Schiller JH, Bonomi P, Johnson DH. Clinical model to predict survival in chemonaive patients with advanced non-small-cell lung cancer treated with third-generation chemotherapy regimens based on eastern cooperative oncology group data. J Clin Oncol. 2005;23: 175-183.
4. Rosell R, Felip E, Garcia-Campelo R, Balaña C. The biology of non-small-cell lung cancer: identifying new targets for rational therapy. Lung Cancer. 2004;46:135-148.
5. Redon C, Pilch DR, Rogakou E, Sedelnikova OA, Newrock K, Bonner WM. Histone H2A variants h2ax and h2az. Curr Opin Genet Dev. 2002; 12:162-169.
6. Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma. 2009;118:683-692.
7. Bonner WM, Redon CE, Dickey JS, et al. GammaH2AX and cancer. Nat Rev Cancer. 2008;8:957-967.
8. Rothkamm K, Lobrich M. Evidence for a lack of DNA double-strand break repair in human cells exposed to very low x-ray doses. Proc Natl Acad Sci USA. 2003;100:5057-5062.
9. Kinner A, Wu W, Staudt C, Iliakis G. Gamma-H2AX in recognition and signaling of DNA double-strand breaks in the context of chromatin. Nucleic Acids Res. 2008;36:5678-5694.
10. Podhorecka M, Skladanowski A, Bozko P. H2AX phosphorylation: its role in DNA damage response and cancer therapy. J Nucleic Acids. Epub August 3, 2010.
11. Redon CE, Nakamura AJ, Martin OA, Parekh PR, Weyemi US, Bonner WM. Recent developments in the use of γ-H2AX as a quantitative DNA double-strand break biomarker. Aging (Albany N Y). 2011;3:168-174.
12. Zhang H P, Singer B. Recursive Partitioning in the Health Sciences. New York: Springer; 1999.
13. Goldstraw P. The 7th edition of TNM in Lung Cancer: what now? J Thorac Oncol. 2009;4:671-673.
14. Giatromanolaki A, Koukourakis MI, Kakolyris S, et al. Vascular endothelial growth factor, wild-type p53, and angiogenesis in early operable non-small cell lung cancer. Clin Cancer Res. 1998;4: 3017-3024.
15. Hommura F, Dosaka-Akita H, Mishina T, et al. Prognostic significance of p27 KIP1 protein and ki-67 growth fraction in non-small cell lung cancers. Clin Cancer Res. 2000;6:4073-4081.
16. Bartek J, Lukas J. Mammalian G1- and S-phase checkpoints in response to DNA damage. Curr Opin Cell Biol. 2001;13:738-747.
17. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. Oncogene. 2005;24:2899-2908.
18. Moldovan GL, Pfander B, Jentsch S. PCNA, the maestro of the replication fork. Cell. 2007;129:665-679.
19. Gartel AL, Radhakrishnan SK. Lost in transcription: p21 repression, mechanisms, and consequences. Cancer Res. 2005;65:3980-3985.
20. Liu G, Lozano G. p21 Stability: linking chaperones to a cell cycle checkpoint. Cancer Cell. 2005;7:113-114.
21. Gottifredi V, McKinney K, Poyurovsky M V, Prives C. Decreased p21 levels are required for efficient restart of DNA synthesis after S phase block. J Biol Chem. 2004;279:5802-5810.
22. Tian H, Wittmack EK, Jorgensen TJ. p21 WAF1/CIP1 antisense therapy radiosensitizes human colon cancer by converting growth arrest to apoptosis. Cancer Res. 2000;60:679-684.
23. Suzuki A, Tsutomi Y, Miura M, Akahane K. Caspase 3 inactivation to suppress Fas-mediated apoptosis: identifcation of binding domain with p21 and ILP and inactivation machinery by p21. Oncogene. 1999; 18:1239-1244.
24. Ishida H, Irie K, Itoh T, Furukawa T, Tokunaga O. The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction. Cancer. 1997;15:1034-1045.
25. Gorgoulis VG, Zacharatos P, Kotsinas A, et al. Altered expression of the cell cycle regulatory molecules pRb, p53 and MDM2 exert a synergetic effect on tumor growth and chromosomal instability in non-small cell lung carcinomas (NSCLCs). Mol Med. 2000;6:208-237.
26. Halazonetis TD, Gorgoulis VG, Bartek J. An oncogene-induced DNA damage model for cancer development. Science. 2008;319: 1352-1355.
27. Brunner AH, Hinterholzer S, Riss P, Heinze G, Weiss K, Brustmann H. Expression of γ-H2AX in endometrial carcinomas: an immunohis- tochemical study with p53. Gynecol Oncol. 2011;121:206-211.
28. Nagelkerke A, van Kuijk SJ, Sweep FC, et al. Constitutive expression of γ-H2AX has prognostic relevance in triple negative breast cancer. Radiother Oncol. 2011;101:39-45.
29. Berghmans T, Paesmans M, Sculier J P. Prognostic factors in stage III non-small cell lung cancer: a review of conventional, metabolic and new biological variables. Ther Adv Med Oncol. 2011;3:127-138.
30. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet. 2011;378:1727-1740.